{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=103", "query": { "intervention": "SC", "page": 103 }, "page_size": 10 }, "pagination": { "page": 103, "page_size": 10, "total_count": 3872, "total_pages": 388, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=104&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=102&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T03:33:57.738Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07518186", "title": "A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "JNJ-79635322", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2026-05-31", "completion_date": "2032-12-08", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07518186" }, { "nct_id": "NCT01177683", "title": "Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sherif Farag, MB, BS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2010-07", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 7, "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Wyoming, Michigan + 2 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Wyoming", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01177683" }, { "nct_id": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "FHD-286", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-02-03", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07283094" }, { "nct_id": "NCT04554966", "title": "Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "ABBV-382", "type": "DRUG" }, { "name": "Placebo for ABBV-382", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2021-04-16", "completion_date": "2023-08-14", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 19, "location_summary": "Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04554966" }, { "nct_id": "NCT02963766", "title": "A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 154, "start_date": "2016-12-29", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02963766" }, { "nct_id": "NCT04305405", "title": "PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Uncontrolled Asthma" ], "interventions": [ { "name": "Benralizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "6 Years to 14 Years" }, "enrollment_count": 30, "start_date": "2019-11-21", "completion_date": "2022-09-12", "has_results": true, "last_update_posted_date": "2023-05-18", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 7, "location_summary": "Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305405" }, { "nct_id": "NCT06083922", "title": "A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Monoclonal Gammopathy of Renal Significance" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-10-16", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 11, "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06083922" }, { "nct_id": "NCT01838395", "title": "Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ara-C", "type": "DRUG" }, { "name": "BL-8040", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2013-04", "completion_date": "2023-07-20", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 5, "location_summary": "Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838395" }, { "nct_id": "NCT03689972", "title": "A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 585, "start_date": "2018-11-27", "completion_date": "2023-07-24", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 52, "location_summary": "Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03689972" }, { "nct_id": "NCT05347095", "title": "A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fistulizing Crohns Disease", "Perianal Crohns Disease" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2022-09-27", "completion_date": "2027-03-25", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-10T03:33:57.738Z", "location_count": 15, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05347095" } ] }